Standard Biotools Inc
LABNASDAQStock · Data from SEC EDGAR 13F · Held by 1 of 87 tracked investors
Standard Biotools Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth13
- Profitability50
- Quality20
- Debt100
- Stability25
- ✓Out of 100 USD of revenue, 100 USD is left as net profit.
- ✓It has more cash than debt.
- ✓The analysts' average target is 119% above the price.
- !Revenue fell 4.5% a year over 3 years.
- !In some year revenue fell sharply.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 2.9×
- EV/EBITDA
- 3.9×
Is the company growing?
ShrinkingRevenue over 3 years grew -4.5% a year. Last year -7.6%.
Does it make money?
Excellent- Cost of sales 50
Chart LAB
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
1AH Andreas Halvorsen Viking Global Investors | 0.14% |
Frequently asked questions
How much is Standard Biotools Inc (LAB) stock?
Standard Biotools Inc shares trade at $0.62, +2.68% over the last trading day. The price is delayed.
What is the market cap of Standard Biotools Inc?
The market cap of Standard Biotools Inc is about $243M.
Which big investors hold Standard Biotools Inc?
According to the latest 13F filings, 1 of 87 tracked investors hold Standard Biotools Inc, for example Andreas Halvorsen.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.